Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 486 participants.
Also called NCT06362746
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 486 participants
- Sponsor
- Registry
-
NCT06362746
-
- Other papers using this trial's data
- Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Recruiting
Technical summary
Registry record NCT06362746. Randomized; double masking; primary purpose treatment. Start 2024-05-23 (actual); primary completion 2028-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
- Condition
- Pulmonary Embolism
- Intervention (Drug)
- Non-immunogenic recombinant staphylokinase
- Intervention (Drug)
- Placebo
- Lead sponsor
- Supergene, LLC
Record details
- Record id
cardio:ct-nct06362746- Content hash
10c78d8643e6605f88a95508b8028a884242775d04d3c33f5c7c943917e0523f